FDA
-
-
-
-
-
-
-
H.C. Wainwright Starts Gracell Biotechnologies Inc (GRCL) at Buy
-
-
-
-
-
-
-
Gracell Biotechnologies' Abstract on GC012F, a BCMA/CD19 Dual-targeting CAR-T Cell Therapy, Accepted for Presentation at 2022 ASCO Annual Meeting
-
-
-
-
-
-
-
Gracell Biotechnologies Reports Long-term Follow-up Data on TruUCAR-enabled GC027 in Relapsed/Refractory T-ALL at the AACR 2021 Annual Meeting
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

